The approval was supported by data from the phase 3 OPTIMA trial, which enrolled 63 adults with FOP confirmed by an ACVR1 FOP ...
Intismeran autogene is a personalized mRNA therapy that targets a tumor's unique mutational signature to trigger an anticancer immune response.
Coverage slipped for every required shot, with declines in more than half of states for a second straight year.
Most cases accounted for by medication-related exposures, with acetaminophen alone most frequently implicated.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results